Ropivacaine extended release - Encore/PainReform

Drug Profile

Ropivacaine extended release - Encore/PainReform

Alternative Names: ETI-211 - Encore; F-93; LNP-oily solution; LNP-oily solution (Ropivacaine); PRF-108

Latest Information Update: 06 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Encore Therapeutics
  • Class Amides; Local anaesthetics; Piperidines; Small molecules
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Postoperative pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Jan 2016 No development reported - Phase-I/II for Postoperative pain in Israel (SC)
  • 26 Sep 2011 Ropivacaine depot is available for licensing as of 26 Sep 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top